Acceleron Pharma Inc. (XLRN) on Monday said its investigational therapy ACE-083 for the treatment of facioscapulohumeral muscular dystrophy (FSHD) did not achieve functional secondary endpoints in the Phase 2 trial.
from RTT - Biotech https://ift.tt/32KCxYl
via IFTTT
No comments:
Post a Comment